Gordon R. Bernard Sells 2,050 Shares of Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) Stock

Share on StockTwits

Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) Director Gordon R. Bernard sold 2,050 shares of Cumberland Pharmaceuticals stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $6.19, for a total transaction of $12,689.50. Following the completion of the transaction, the director now directly owns 95,388 shares of the company’s stock, valued at $590,451.72. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Shares of NASDAQ:CPIX opened at $6.30 on Monday. The stock has a market capitalization of $97.88 million, a P/E ratio of -52.50 and a beta of 0.14. Cumberland Pharmaceuticals, Inc. has a fifty-two week low of $4.83 and a fifty-two week high of $7.00. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.67 and a current ratio of 2.07.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its quarterly earnings data on Tuesday, May 14th. The specialty pharmaceutical company reported $0.09 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.22. The firm had revenue of $11.90 million for the quarter, compared to the consensus estimate of $10.70 million. Cumberland Pharmaceuticals had a negative net margin of 10.57% and a positive return on equity of 2.54%. On average, research analysts expect that Cumberland Pharmaceuticals, Inc. will post 0.28 earnings per share for the current fiscal year.

CPIX has been the subject of several research reports. TheStreet raised shares of Cumberland Pharmaceuticals from a “d+” rating to a “c-” rating in a report on Wednesday, April 10th. Zacks Investment Research raised shares of Cumberland Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $7.25 price target for the company in a report on Thursday, May 23rd.

An institutional investor recently raised its position in Cumberland Pharmaceuticals stock. Stonepine Capital Management LLC boosted its position in Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) by 7.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,313,429 shares of the specialty pharmaceutical company’s stock after purchasing an additional 95,028 shares during the quarter. Cumberland Pharmaceuticals comprises 7.0% of Stonepine Capital Management LLC’s holdings, making the stock its 4th biggest position. Stonepine Capital Management LLC owned approximately 8.46% of Cumberland Pharmaceuticals worth $7,920,000 at the end of the most recent quarter. 31.72% of the stock is currently owned by institutional investors and hedge funds.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections.

Recommended Story: Overbought

Insider Buying and Selling by Quarter for Cumberland Pharmaceuticals (NASDAQ:CPIX)

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

China Distance Education  Stock Rating Lowered by Zacks Investment Research
China Distance Education Stock Rating Lowered by Zacks Investment Research
Callon Petroleum  Stock Rating Reaffirmed by Northland Securities
Callon Petroleum Stock Rating Reaffirmed by Northland Securities
Canadian Pacific Railway  Rating Reiterated by Cowen
Canadian Pacific Railway Rating Reiterated by Cowen
CNX Resources  Lowered to “Sell” at Zacks Investment Research
CNX Resources Lowered to “Sell” at Zacks Investment Research
COSTAMARE INC/SH  Stock Rating Upgraded by Zacks Investment Research
COSTAMARE INC/SH Stock Rating Upgraded by Zacks Investment Research
Imperial Capital Lowers Callon Petroleum  Price Target to $11.00
Imperial Capital Lowers Callon Petroleum Price Target to $11.00


© 2006-2019 Ticker Report